NO20065983L - Forbindelser og sammensetninger som PPAR modulatorer - Google Patents

Forbindelser og sammensetninger som PPAR modulatorer

Info

Publication number
NO20065983L
NO20065983L NO20065983A NO20065983A NO20065983L NO 20065983 L NO20065983 L NO 20065983L NO 20065983 A NO20065983 A NO 20065983A NO 20065983 A NO20065983 A NO 20065983A NO 20065983 L NO20065983 L NO 20065983L
Authority
NO
Norway
Prior art keywords
compounds
compositions
ppar
ppar modulators
activity
Prior art date
Application number
NO20065983A
Other languages
English (en)
Norwegian (no)
Inventor
Robert Epple
Yongping Xie
Xing Wang
Christopher Cow
Ross Russo
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of NO20065983L publication Critical patent/NO20065983L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20065983A 2004-05-24 2006-12-22 Forbindelser og sammensetninger som PPAR modulatorer NO20065983L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57413704P 2004-05-24 2004-05-24
US64967105P 2005-02-02 2005-02-02
PCT/US2005/018166 WO2005116016A1 (fr) 2004-05-24 2005-05-24 Composes et compositions servant de modulateurs ppar

Publications (1)

Publication Number Publication Date
NO20065983L true NO20065983L (no) 2007-02-05

Family

ID=35450825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065983A NO20065983L (no) 2004-05-24 2006-12-22 Forbindelser og sammensetninger som PPAR modulatorer

Country Status (17)

Country Link
US (1) US20070244130A1 (fr)
EP (1) EP1749003A4 (fr)
JP (1) JP2008500354A (fr)
KR (1) KR20070043705A (fr)
AR (1) AR049186A1 (fr)
AU (2) AU2005247930B2 (fr)
BR (1) BRPI0511527A (fr)
CA (1) CA2563819A1 (fr)
EC (1) ECSP067019A (fr)
IL (1) IL179375A0 (fr)
MA (1) MA28900B1 (fr)
MX (1) MXPA06013589A (fr)
NO (1) NO20065983L (fr)
PE (1) PE20060362A1 (fr)
RU (1) RU2412175C2 (fr)
TW (1) TW200600505A (fr)
WO (1) WO2005116016A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942921A4 (fr) * 2005-10-25 2011-03-09 Merck Sharp & Dohme Combinaison d'un inhibiteur de dipeptidyl peptidase-4 et d'un agent anti-hypertenseur pour le traitement du diabete et de l'hypertension
RU2008122547A (ru) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
EP2125758A1 (fr) 2007-02-22 2009-12-02 Irm Llc Composés et procédés pour moduler des récepteurs couplés aux protéines g
EP1972335A1 (fr) * 2007-03-23 2008-09-24 Krka Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables
KR100860561B1 (ko) * 2007-05-02 2008-09-26 경희대학교 산학협력단 컴파운드 ｋ 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045529A2 (fr) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Thérapies de combinaison pour le traitement de l'obésité
US20100113604A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113603A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010151503A2 (fr) * 2009-06-25 2010-12-29 Metabolous Pharmaceuticals, Inc. Multithérapies pour le traitement de l'obésité
WO2010151565A2 (fr) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Multithérapies pour le traitement de l'obésité
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
WO2011009115A2 (fr) * 2009-07-17 2011-01-20 Metabolous Pharmaceuticals, Inc. Thérapies combinées destinées à traiter l'obésité
EP2463279B1 (fr) 2009-08-05 2014-02-12 Daiichi Sankyo Company, Limited Composés de 4-(1,2,4-dioxazol-3-yl)benzamide pour le traitement du diabète et de l'obésité
JP5546543B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
WO2011041632A2 (fr) * 2009-10-01 2011-04-07 Metabolous Pharmaceuticals, Inc. Thérapies combinées pour le traitement de l'obésité
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103724289B (zh) * 2013-12-23 2015-08-19 同济大学 (e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及合成方法和应用
CN104402839B (zh) * 2014-10-20 2016-11-02 同济大学 一种(e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及其制备方法
CN108760940A (zh) * 2018-08-03 2018-11-06 安徽省金楠医疗科技有限公司 一种硫酸氢氯吡格雷检测方法
CN112521384B (zh) * 2021-01-13 2021-11-02 湖北大学 溶剂热一锅法合成苯并噻嗪并环戊二烯衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325959A (en) * 1979-08-09 1982-04-20 The Dow Chemical Company Hypoglycemic 4-(((1,3,4, thiadiazolyl)thio)methyl)benzoic acids, ester and amides
JPH0662590B2 (ja) * 1986-09-19 1994-08-17 久光製薬株式会社 新規なベンズオキサゾ−ル誘導体
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
IT1248528B (it) * 1991-06-21 1995-01-19 Pierrel Spa Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
JPH06206805A (ja) * 1992-02-17 1994-07-26 Hisamitsu Pharmaceut Co Inc チロシナーゼ阻害剤及びそれを用いた皮膚外用剤
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
JPH11147881A (ja) * 1997-08-21 1999-06-02 Sankyo Co Ltd ジヒドロベンゾキノン骨格を有する除草性アゾール誘導体
JP2002348281A (ja) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd ５員複素環アルカン酸誘導体

Also Published As

Publication number Publication date
EP1749003A4 (fr) 2010-05-05
KR20070043705A (ko) 2007-04-25
AU2009202673A1 (en) 2009-07-23
IL179375A0 (en) 2007-03-08
EP1749003A1 (fr) 2007-02-07
RU2412175C2 (ru) 2011-02-20
JP2008500354A (ja) 2008-01-10
RU2006145893A (ru) 2008-06-27
US20070244130A1 (en) 2007-10-18
CA2563819A1 (fr) 2005-12-08
AR049186A1 (es) 2006-07-05
AU2005247930A1 (en) 2005-12-08
BRPI0511527A (pt) 2008-01-02
ECSP067019A (es) 2006-12-29
WO2005116016A1 (fr) 2005-12-08
AU2005247930B2 (en) 2009-04-02
TW200600505A (en) 2006-01-01
PE20060362A1 (es) 2006-05-15
MA28900B1 (fr) 2007-10-01
MXPA06013589A (es) 2007-03-15

Similar Documents

Publication Publication Date Title
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
TW200602330A (en) Compounds and compositions as PPAR modulators
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
WO2007056366A3 (fr) Composes et compositions utilises en tant que modulateurs des ppar
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
WO2007089557A3 (fr) Composés et compositions utilisés comme modulateurs de ppar
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20065678L (no) 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20083011L (no) Modulatorer av muskarine receptorer
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
DE602006016323D1 (de) Oxazol- und thiazol-verbindungen als ppar-modulatoren
NO20083045L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application